Table 1 Baseline characteristics
From: Medical complexity and time to lung cancer treatment – a three-year retrospective chart review
Variables | Total | 2011 | 2012 | 2013 | Non-complex patientsa | Complex patientsb |
|---|---|---|---|---|---|---|
N = 469 | n = 147 | n = 146 | n = 156 | n = 262 | n = 187 | |
Age, median (range) | 72 (40–93) | 70 (40–90) | 71 (46–91) | 73 (54–93) | 72 (46–93) | 72 (40–89) |
Age ≥ 70 years, n (%) | 265 (59%) | 77 (52%) | 84 (57%) | 104 (67%) | 155 (59%) | 110 (59%) |
Women | 206 (46%) | 62 (42%) | 76 (52%) | 68 (44%) | 125 (48%) | 81 (43%) |
TNM stage | ||||||
I | 112 (25%) | 29 (20%) | 39 (27%) | 44 (28%) | 65 (25%) | 47 (25%) |
II | 42 (9%) | 19 (13%) | 10 (7%) | 13 (8%) | 18 (7%) | 24 (13%) |
III | 116 (26%) | 43 (29%) | 34 (23%) | 39 (25%) | 68 (26%) | 48 (26%) |
IV | 179 (40%) | 56 (38%) | 63 (43%) | 60 (38%) | 111 (42%) | 68 (36%) |
Histology | ||||||
NSCLC | 312 (69%) | 105 (71%) | 110 (75%) | 97 (62%) | 161 (61%) | 151 (81%) |
SCLC | 65 (14%) | 18 (12%) | 19 (13%) | 28 (18%) | 49 (19%) | 16 (9%) |
Other primary lung cancers | 9 (2%) | 2 (1%) | 1 (1%) | 6 (4%) | 4 (2%) | 5 (3%) |
No tissue diagnosis | 63 (14%) | 22 (15%) | 17 (11%) | 25 (16%) | 48 (18%) | 15 (8%) |
Treatment | ||||||
Surgery | 116 (26%) | 37 (25%) | 39 (27%) | 40 (26%) | 59 (23%) | 57 (30%) |
Curative radiotherapyc | 74 (16%) | 18 (12%) | 22 (15%) | 34 (22%) | 46 (18%) | 28 (15%) |
Palliative radiotherapy | 48 (11%) | 19 (13%) | 15 (10%) | 14 (9%) | 26 (10%) | 22 (12%) |
Palliative systemic therapy | 120 (27%) | 38 (26%) | 43 (29%) | 39 (25%) | 69 (26%) | 51 (27%) |
Palliative surgery | 5 (1%) | 1 (1%) | 1 (1%) | 3 (2%) | 2 (1%) | 3 (2%) |
No cancer treatment | 79 (18%) | 31 (21%) | 24 (16%) | 24 (15%) | 55 (21%) | 24 (13%) |
Death before treatment | 7 (2%) | 3 (2%) | 2 (1%) | 2 (1%) | 5 (2%) | 2 (1%) |
Out-patient investigation | 290 (65%) | 93 (63%) | 98 (67%) | 99 (63%) | 163 (62%) | 127 (68%) |
PET CT | 146 (33%) | 15 (10%) | 52 (36%) | 79 (51%) | 79 (30%) | 67 (36%) |